블로그
- The human cell is wildly complex. Can AI decode it?- Silvana Konermann (2026) https://www.ted.com/talks/silvana_konermann_the_human_cell_is_wildly_complex_can_ai_decode_it 어렸을 적 생물학에 매료되었습니다. 생물학은 세포의 언어를 탐구하는 학문이니까요. 세포의 언어는 인간의 언어와 매우 다
- [대식세포 고갈/제거 시약: Macrophage depletion reagent] Clodronate liposome (클로드로네이트 리포좀)_Xygieia Bioscience Clodronate itself is known to be difficult to pass through a cell membrane and to be incorporated by Clodronate liposome has efficient cell permea.......
- Dextran 2000 - MW: 1,500,000 to 3,500,000 [OD156913][CAS no. 9004-54-0]_Biosynth - 코아사이언스 .# OD156913 / Size: 5g, 10g, 25g, 50g, 100g Specification / MSDS Dextran 2000 is a high molecular weight It is used in a variety of medical applications, such as red blood cell transfusions and the prevention
- [Funakoshi Newsletter Vol.178] Natural bioactive compounds for cancer cell proliferation suppression [Funakoshi Newsletter Vol. 178] Natural bioactive compounds for cancer cell proliferation suppression DMSO Solution type is also available! NOTICE : FOR RESEARCH USE ONLY. NOT .......
- Astaxanthin [B1370-051438][CAS no. 472-61-7]_BOC Sciences - 코아사이언스 It is thought to be the precursor of astacin. It is a potent lipid-soluble antioxidant. and its antioxidant capacity is much higher than VE and β-carotene.
- TF 인터뷰 티파니 영 “Yumi’s Cells is a story that belongs to everyone. I hope people can always come and visit Cell Village.”
- 14108. Definition of Buddha (4_4) Hwaseong It is extremely important that we understand Buddha accurately. But what is an illness?
- Paclitaxel-MVCP [620102][CAS no. 2119034-12-5]_MedKoo Biosciences - 코아사이언스 # 620102 / Size: 1mg, 2mg, 5mg, 10mg, 25mg Description: Paclitaxel-MVCP (MC-Val-Cit-PAB-Paclitaxel) is The MC-Val-Cit-PAB linker is designed for high plasma stability and efficient intracellular release of
- [Ready-to-Use type of iMatrix-511/iMatrix-511 silk] Easy iMatrix-511 / Easy iMatrix-511 silk Single cell passaging is possible. When 1.5 mL is used for 1 well (9.6 cm2) .......
- [U.S. FDA] FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications Food and Drug Administration today approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell
1 페이지
다음 →